Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study

Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study

BackgroundAmong the advantaged population with clinical cure of chronic hepatitis B, chronic inactive hepatitis B virus carriers (IHCs) and nucleoside analog-experienced patients have similar serological manifestations. This study established non-interferon-treated groups as controls to compare the...

Full description

Bibliographic Details
Main Authors:	Chaojing Wen, Yixuan Wang, Haoyue Tian, Yu Lei, Zhiyi Wang, Dachuan Cai, Zhi Zhou, Xiaofeng Shi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Series:	Frontiers in Cellular and Infection Microbiology
Subjects:	clinical cure chronic inactive hepatitis B virus carriers nucleoside analog-experienced patients HBsAg clearance HBsAg seroconversion pegylated interferon α-2b
Online Access:	https://www.frontiersin.org/articles/10.3389/fcimb.2023.1332232/full

Similar Items

Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon
by: Hong Li, et al.
Published: (2022-12-01)

Functional Cure of Hepatitis B Virus Infection in Individuals With HIV-Coinfection: A Literature Review
by: Anders Boyd, et al.
Published: (2021-07-01)

Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients treated with nucleotide analogs plus polyethylene glycol interferon
by: Yan Peng, et al.
Published: (2025-01-01)

The impact of hepatitis B surface antigen seroconversion on the durability of functional cure induced by pegylated interferon alpha treatment
by: Wencong Zhang, et al.
Published: (2024-10-01)

Clinical Outcomes and Quantitative HBV Surface Antigen Levels in Diverse Chronic Hepatitis B Patients in Canada: A Retrospective Real-World Study of CHB in Canada (REVEAL-CANADA)
by: Carla S. Coffin, et al.
Published: (2022-11-01)

RNA Interference Therapy for Chronic Hepatitis B Predicts the Importance of Addressing Viral Integration When Developing Novel Cure Strategies
by: Christine I. Wooddell, et al.
Published: (2021-03-01)

Predicting clinical outcomes in chronic hepatitis B patients receiving nucleoside analogues and pegylated interferon alpha: a hematochemical and clinical analysis
by: Shuang Xu, et al.
Published: (2024-10-01)

Interferon add-on therapy increased clinical cure significantly for interferon-experienced chronic hepatitis B patients with low HBsAg
by: Xiaoan Yang, et al.
Published: (2022-09-01)

Durability of Hepatitis B surface antigen seroclearance in patients experienced nucleoside analogs or interferon monotherapy: A real-world data from Electronic Health Record
by: Zongqi Shi, et al.
Published: (2023-05-01)

Peg-IFNα combined with hepatitis B vaccination contributes to HBsAg seroconversion and improved immune function
by: Yisi Liu, et al.
Published: (2024-03-01)

Comparative ELISA reagents for detection of hepatitis B surface antigen (HBsAg) Comparação de reativos para o teste de ELISA na evidenciação do antígeno de superfície de hepatite B
by: I. F. Camargo, et al.
Published: (1987-06-01)

A predictive model for functional cure in chronic HBV patients treated with pegylated interferon alpha: a comparative study of multiple algorithms based on clinical data
by: Ya-mei Ye, et al.
Published: (2024-12-01)

Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies
by: Lorenzo Piermatteo, et al.
Published: (2023-12-01)

Transaminase Elevations during Treatment of Chronic Hepatitis B Infection: Safety Considerations and Role in Achieving Functional Cure
by: Andrew Vaillant
Published: (2021-04-01)

Analytical Performance of the Sysmex HISCL HBsAg Assay and Comparison with the Roche Elecsys HBsAg II Quant Assay in the Quantification of Hepatitis B Surface Antigen
by: Joonhong Park, et al.
Published: (2021-11-01)

Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-neegative chronic hepatitis B: A multicentre cohort study
by: Milan J. Sonneveld, et al.
Published: (2023-08-01)

Accuracy Validation of the Elecsys HBsAg II Quant Assay and Its Utility in Resolving Equivocal Qualitative HBsAg Results
by: Jaehyeon Lee, et al.
Published: (2023-02-01)

Geographic distribution of HBsAg subtypes in Brazil Distribuição geográfica dos subtipos de antígenos de HBsAg no Brasil
by: Ana Maria Coimbra Gaspar, et al.
Published: (1987-06-01)

Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection
by: Romina Salpini, et al.
Published: (2020-01-01)

Epidemiology of Chronic Hepatitis B Infection in the Cohort of College Students with Vaccination in Taiwan
by: Te-Wei Cheng, et al.
Published: (2023-02-01)

Serum IL-5 levels predict HBsAg seroclearance in patients treated with Nucleos(t)ide analogues combined with pegylated interferon
by: Peipei Wang, et al.
Published: (2023-01-01)

Clinical study of hepatitis B vaccine in achieving hepatitis B surface antibody seroconversion in patients with functional cure
by: Yisi Liu, et al.
Published: (2023-11-01)

Long-Term HBsAg Titer Kinetics with Entecavir/Tenofovir: Implications for Predicting Functional Cure and Low Levels
by: Soon Kyu Lee, et al.
Published: (2024-02-01)

Surveillance Following Hepatitis B Surface Antigen Loss: An Issue Requiring Attention
by: Shuai-Wen Huang, et al.
Published: (2024-12-01)

Elimination of Hepatitis B in Highly Endemic Settings: Lessons Learned in Taiwan and Challenges Ahead
by: Chun-Jen Liu, et al.
Published: (2020-07-01)

Seroepidemiology of hepatitis a and b in two urban communities of Rio de Janeiro, Brazil
by: Abdulbasit R. N. Abuzwaida, et al.
Published: (1987-08-01)

Natural History and Hepatitis B Virus Surface Antigen (HBsAg) Spontaneous Seroclearance in Hepatitis B Virus e-Antigen (HBeAg)-Negative Patients with Inactive Chronic Infection: A Multicenter Regional Study from South Italy
by: Michele Barone, et al.
Published: (2023-09-01)

An Increase in the Levels of Middle Surface Antigen Characterizes Patients Developing HBV-Driven Liver Cancer Despite Prolonged Virological Suppression
by: Giuseppina Brancaccio, et al.
Published: (2021-04-01)

Protection against hepatitis B by the Butang® recombinant vaccine in newborn children in South Brazil
by: Aline Paula Isolani, et al.
Published: (2006-08-01)

Baseline HBsAg quantitative and CD4 T cell counts are associated with HBsAg loss in people living with HIV/HBV coinfection after combined antiretroviral therapy
by: Muye Xia, et al.
Published: (2025-02-01)

TREND IN SEROPREVALENCE OF HEPATITIS B VIRUS INFECTION AMONG BLOOD DONORS AT A TERTIARY CARE CENTRE OF RAJASTHAN, INDIA
by: Poojaba Jadeja, et al.
Published: (2014-09-01)

Serological Evaluation of Hepatitis B Virus in Out Patient Department Patients of a Private Hospital in North-West India
by: Smita Sood
Published: (2013-09-01)

Correlation between quantitative HBsAg and quantitative HBV DNA in chronic hepatitis B patients: a systematic review and meta-analysis
by: Ummi Maimunah, et al.
Published: (2024-05-01)

The presence of baseline HBsAb-Specific B cells can predict HBsAg or HBeAg seroconversion of chronic hepatitis B on treatment
by: Shengxia Yin, et al.
Published: (2023-12-01)

Kinetics and Value of Hepatitis B Core-Related Antigen in Patients with Chronic Hepatitis B Virus Infection during Antiviral Treatment
by: Lisa Sandmann, et al.
Published: (2024-02-01)

The effectiveness of hepatitis B vaccine in toddlers based on the five-year period national basic health research (Riskesdas 2007, 2013 and 2018) in Indonesia
by: Christina Safira Whinie Lestari, et al.
Published: (2023-05-01)

Analysis of S gene characteristic sequences and changes in properties of protein expression in HBV ASCs with low-level HBsAg
by: Yu Yu, et al.
Published: (2022-09-01)

Hepatitis B Virus Reactivation upon Immunosuppression: Is There a Role for Hepatitis B Core-Related Antigen in Patients with Immune-Escape Mutants? A Case Report
by: Gian Paolo Caviglia, et al.
Published: (2021-11-01)

Prediction Model for the Clearance of Hepatitis B Surface Antigen in Patients with Chronic Hepatitis B before Interferon Therapy: A Prospective Case–Control Study
by: Nan Geng, et al.
Published: (2024-01-01)

Impact of HBcrAg levels on HBsAg seroconversion after HBV rebound: a case report
by: Maki Ohkubo, et al.
Published: (2023-12-01)